BACKGROUND/AIMS
Genetic variants in PNPLA3, TM6SF2, MBOAT7, GCKR, and HSD17B13 have been associated with MASLD progression and hepatocellular carcinoma (HCC). We evaluated their associations with prevalent HCC and the performance of a five-variant polygenic risk score (PRS-5) in Korean patients with MASLD.
METHODS
A...
Jaejun Lee, J. Cha, Hee Sun Cho et al.· Journal of Gastroenterology...· 0 citations
BACKGROUND
Alcohol-associated liver disease (ALD) is a major cause of morbidity, yet therapies for severe inflammation remain limited.
OBJECTIVE
We examined whether circulating and hepatic immunoglobulin A (IgA) and hepatic myeloid-cell IgA binding are associated with interleukin-1 beta (IL-1β)-linked inflammation an...
Min Gu Kim, K. Tak, D. Seo et al.· Gut· 0 citations
Background/purpose Atezolizumab–bevacizumab (AB) and durvalumab–tremelimumab (DT) are standard first-line therapies for unresectable hepatocellular carcinoma (uHCC), but their comparative effectiveness remains uncertain. Methods We included 76 observational reports comprising 10,243 patients. Report-level median surviv...
Jongin Lee, K. Tak, Hee Sun Cho et al.· Frontiers in Immunology· 0 citations
In patients with advanced HCC, after AB failure, second-line HAIC yielded higher response rates and longer PFS than TKIs, and after IPTW, HAIC remained associated with longer PFS than TKIs.
Jae-Sung Yoo, K. Tak, Hee Sun Cho et al.· Radiology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
